Tags

Type your tag names separated by a space and hit enter

The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease.
Eur J Gastroenterol Hepatol 2003; 15(10):1115-21EJ

Abstract

OBJECTIVE

To evaluate the efficiency of the 5-HT4 agonist and 5-HT3 antagonist mosapride, as compared with cisapride, on oesophageal acid reflux variables and oesophageal motor function in patients with chronic gastro-oesophageal reflux disease (GORD).

METHOD

Forty-one patients with proven GORD were included in a double-blind, randomised, double-dummy, three-way crossover study. All patients received mosapride 60 mg twice daily, mosapride 30 mg three times daily, and cisapride 20 mg twice daily for seven days in a randomised order, separated by a washout period of at least five days. Twenty-three patients underwent four combined ambulatory 24-h motility and pH recordings within two weeks before the start of treatment and on day seven of each treatment period. The remaining 18 patients underwent three ambulatory 24-h pH recordings only, i.e. on treatment day seven of each treatment period.

RESULTS

Mosapride had no significant effect on the total number of contractions in the oesophagus, or on the effectiveness, or possible effectiveness, of the propagations. Significant but numerically small effects on peristaltic durations and amplitudes were noted during both mosapride and cisapride treatment as compared with baseline values. The effect on acid reflux for both mosapride and cisapride was most pronounced for the duration of the longest reflux episode. The fraction of time with pH less than 4 was reduced by mosapride 30 mg three times daily in the supine position and by cisapride both totally and in the supine position. The number of reflux episodes was reduced significantly only by cisapride. Oesophageal clearance was reduced significantly by cisapride only in the supine position.

CONCLUSION

Mosapride had small but statistically significant effects, comparable to those of cisapride, on acid reflux variables and oesophageal motor function in patients with GORD.

Authors+Show Affiliations

Department of Otorhinolaryngology, Sahlgrenska University Hospital, Göteborg, Sweden. magnus.ruth@vgregion.seNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14501621

Citation

Ruth, Magnus, et al. "The Effect of Mosapride On Oesophageal Motor Function and Acid Reflux in Patients With Gastro-oesophageal Reflux Disease." European Journal of Gastroenterology & Hepatology, vol. 15, no. 10, 2003, pp. 1115-21.
Ruth M, Finizia C, Cange L, et al. The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2003;15(10):1115-21.
Ruth, M., Finizia, C., Cange, L., & Lundell, L. (2003). The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. European Journal of Gastroenterology & Hepatology, 15(10), pp. 1115-21.
Ruth M, et al. The Effect of Mosapride On Oesophageal Motor Function and Acid Reflux in Patients With Gastro-oesophageal Reflux Disease. Eur J Gastroenterol Hepatol. 2003;15(10):1115-21. PubMed PMID: 14501621.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. AU - Ruth,Magnus, AU - Finizia,Caterina, AU - Cange,Lars, AU - Lundell,Lars, PY - 2003/9/23/pubmed PY - 2003/12/12/medline PY - 2003/9/23/entrez SP - 1115 EP - 21 JF - European journal of gastroenterology & hepatology JO - Eur J Gastroenterol Hepatol VL - 15 IS - 10 N2 - OBJECTIVE: To evaluate the efficiency of the 5-HT4 agonist and 5-HT3 antagonist mosapride, as compared with cisapride, on oesophageal acid reflux variables and oesophageal motor function in patients with chronic gastro-oesophageal reflux disease (GORD). METHOD: Forty-one patients with proven GORD were included in a double-blind, randomised, double-dummy, three-way crossover study. All patients received mosapride 60 mg twice daily, mosapride 30 mg three times daily, and cisapride 20 mg twice daily for seven days in a randomised order, separated by a washout period of at least five days. Twenty-three patients underwent four combined ambulatory 24-h motility and pH recordings within two weeks before the start of treatment and on day seven of each treatment period. The remaining 18 patients underwent three ambulatory 24-h pH recordings only, i.e. on treatment day seven of each treatment period. RESULTS: Mosapride had no significant effect on the total number of contractions in the oesophagus, or on the effectiveness, or possible effectiveness, of the propagations. Significant but numerically small effects on peristaltic durations and amplitudes were noted during both mosapride and cisapride treatment as compared with baseline values. The effect on acid reflux for both mosapride and cisapride was most pronounced for the duration of the longest reflux episode. The fraction of time with pH less than 4 was reduced by mosapride 30 mg three times daily in the supine position and by cisapride both totally and in the supine position. The number of reflux episodes was reduced significantly only by cisapride. Oesophageal clearance was reduced significantly by cisapride only in the supine position. CONCLUSION: Mosapride had small but statistically significant effects, comparable to those of cisapride, on acid reflux variables and oesophageal motor function in patients with GORD. SN - 0954-691X UR - https://www.unboundmedicine.com/medline/citation/14501621/The_effect_of_mosapride_on_oesophageal_motor_function_and_acid_reflux_in_patients_with_gastro_oesophageal_reflux_disease_ L2 - http://Insights.ovid.com/pubmed?pmid=14501621 DB - PRIME DP - Unbound Medicine ER -